Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: A new-user cohort study

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  DiSantostefano, Rachael L ^a   Sampson, Tim ^a   Van Le, Hoa ^a   Hinds, David ^a   Davis, Kourtney J ^a   Bakerly, Nawar Diar ^b  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; ELECTRONIC MEDICAL RECORD; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; OBSERVATIONAL STUDY; PNEUMONIA; PROPENSITY SCORE; UNITED KINGDOM; VERY ELDERLY; COMPLICATION; DOSE RESPONSE; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRONCHODILATOR AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK;

EID: 84902332605     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097149     Document Type: Article

References (57)

1. Holguin F, Folch E, Redd SC, Mannino DM (2005) Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 128: 2005-2011. (Pubitemid 41507534)
2. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL (2005) Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 128: 2099-2107. (Pubitemid 41507547)
3. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A (2006) COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 28:346-351. (Pubitemid 44914234)
4. Molinos L, Clemente MG, Miranda B, Alvarez C, del Busto B, et al. (2009) Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 58: 417-424.
5. Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, et al. (2011) Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 139: 505-512.
6. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, et al. (2009) Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 34: 641-647.
7. Mannino DM, Davis KJ, Kiri VA (2009) Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med 103: 224-229.
8. Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, et al. (2012) The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 106: 1124-1133.
9. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ (2012) Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 106: 257-268.
10. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E (2008) Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300: 2407-216.
11. Singh S, Loke YK (2010) Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med 16: 118-122.
12. 2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 12: CD007033
13. Nannini LJ, Lasserson TJ, Poole P (2012) Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 9: CD006829.
14. Ernst P, Gonzalez AV, Brassard P, Suissa S (2007) Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 176: 162-166. (Pubitemid 47057852)
15. Joo MJ, Au DH, Fitzgibbon ML, Lee TA (2010) Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 104: 246-252.
16. Thornton Snider J, Luna Y, Wong KS, Zhang J, Chen SS, et al. (2012) Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. Curr Med Res Opin 28: 1959-1967.
17. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, et al. (2006) Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173: 736-743.
18. Guess HA (2006) Exposure-time-varying hazard function ratios in case-control studies of drug effects. Pharmacoepidemiol Drug Saf 15: 81-92.
19. Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158: 915-920.
20. DiSantostefano RL, Sampson T, Van Le H, Davis KJ, Bakerly N (2013) A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilators (LABD) regimens in COPD. Eur Respir J (Suppl 57): 1005-1006s.
21. García Rodríguez LA, Pérez-Gutthann S, Jick S (2002) The UK General Practice Research Database. In: Strom B, editor. Pharmacoepidemiology 3rd edJohn Wiley & Sons, Ltd. pp. 375-385.
22. Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D (1999) Use of the general research practice database (GPRD) for respiratory epidemiology: a comparison with the 4th morbidity survey in general practice. Thorax 54: 413-419. (Pubitemid 29199779)
23. Soriano JB, Maier WC, Visick G, Pride NB (2001) Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 17: 1075-1080.
24. Meropol SB, Metlay JP (2012) Accuracy of pneumonia hospital admissions in a primary care electronic medical record database. Pharmacoepidemiol Drug Saf 21: 659-665.
25. Schneider C, Bothner U, Jick SS, Meier CR (2010) Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 25: 253-260.
26. Hospital Episode Statistics. Health & Social Care Information Centre. Available at: http://www.hscic.gov.uk/hes. Accessed: 12 March 2014.
27. Office for National Statistics. The 21st Century Mortality Files, 2001-2010. Released 18 November 2011. Available at: http://www.ons.gov.uk/ons/ rel/subnational-health1/the-21st-century-mortality-files/2010/index.html. Accessed: 12 March 2014.
28. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. WEUSKOP6416: Evaluating severe events in patients with Chronic Obstructive Pulmonary Disease (COPD) to inform risk minimization: A Retrospective Observational Study. Available at: http://www.encepp.eu/encepp/ studyRegistration.htm?resumeLabel=ENCEPP/SDPP/4093&adminEmail= cdr-mailbox%40gsk.com&approveFlag=study. Accessed: 12 March 2014.
29. Global Initiative for Chronic Obstructive Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease (2014). Available at: http://www.goldcopd.org/uploads/users/files/GOLD- Report2014-Feb07.pdf.Accessed: 12 March 2014.
30. Pereira JM, Paiva JA, Rello J (2012) Assessing severity of patients with community-acquired pneumonia. Semin Respir Crit Care Med 33: 272-283.
31. Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, et al. (2011) Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 105: 435-441.
32. Jara M, Wentworth C 3rd, Lanes S. (2012) A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. BMJ Open 2: e000841.
33. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) (2012). Available from: http://www.ginasthma.org/local/ uploads/files/GINA-Report-March13.pdf. Accessed: 12 March 2014.
34. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ (2006) Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 333: 999.
35. Arai T, Sekizawa K, Ohrui T, Fujiwara H, Yoshimi N, et al. (2005) ACE inhibitors and protection against pneumonia in elderly patients with stroke. Neurology 64: 573-574. (Pubitemid 40189891)
36. Khan NF, Perera R, Harper S, Rose PW (2010) Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 11: 1.
37. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC (2000) Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 20: 1245-1259.
38. Obiora E, Hubbard R, Sanders RD, Myles PR (2013) The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax 68: 163-170.
39. The English Indices of Deprivation 2007. Communities and Local Government. March 2008. Available at: http://webarchive.nationalarchives.gov.uk/ 20120919132719/http://www.communities.gov.uk/documents/communities/pdf/733520. pdf. Accessed 14 March 2014.
40. Quality and Outcomes Framework (QOF) guidance 2013-2014 (sixth revision). British Medical Association. March 2013. Available at: http://bma.org.uk/ practical-support-at-work/contracts/independent-contractors/qof-guidance. Accessed: 12 March 2014.
41. Robins JM (1998) Marginal structural models. In: 1997 Proceedings of the Section on Bayesian Statistical Science, Alexandria, VA: American Statistical Association, pp. 1-10.
42. Robins JM (1999) Marginal structural models versus structural nested models as tools for causal inference. In: Halloran E, Berry D, editors. Statistical Models in Epidemiology: The Environment and Clinical Trials. New York: Springer-Verlag. pp. 95-134.
43. Robins JM, Hernán M, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-560. (Pubitemid 30660034)
44. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, et al. (2006) A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 59: 437-447.
45. Rubin DB (2004) On principles for modeling propensity scores in medical research. Pharmacoepidemiol Drug Saf 13: 855-857.
46. Schneeweiss S (2010) A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 19: 858-868.
47. Tamim H, Monfared AA, LeLorier J (2007) Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf 16: 250-258. (Pubitemid 46431688)
48. Silverstein F, Simon L, Faich G (2001) Reporting of 6-month vs 12-month data in a clinical trial of Celecoxib - Reply. JAMA 286: 2398-2400. (Pubitemid 33098155)
49. Lambert BL, Chang KY, Tafesse E, Carson W (2005) Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia. J Clin Psychopharmacol 25: 12-18. (Pubitemid 40129377)
50. BREO ELLIPTA (Fluticasone Furoate/Vilanterol Inhalation Powder) For Treatment of Chronic Obstructive Pulmonary Disease. NDA204275. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM347931.pdf. Accessed 12 March 2014.
51. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, et al. (2013) Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallelgroup, randomised controlled trials. Lancet Respir Med 1: 210-223.
52. Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, et al. (2013) Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 68: 256-262.
53. Dong YH, Chang CH, Wu FL, Shen LJ, Calverley PM, et al (2014) Use of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease and the Risk of Tuberculosis and Influenza: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Chest. 2014 Feb 6. doi: 10.1378/chest.13-2137. [Epub ahead of print].
54. Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH (2013) Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis 8: 295-304.
55. Suissa S, Patenaude V, Lapi F, Ernst P (2013) Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 68: 1029-1036.
56. 2 agonist: observational matched cohort study (PATHOS). BMJ 346: f3306.
57. Miettinen OS (1976) Estimability and estimation in case-referent studies. Am J Epidemiol 103: 226-235.